Who are Drug: Carfilzomib + Dexamethasone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bortezomib +Dexamethasone regimen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/drug-carfilzomib-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Drug: Carfilzomib + Dexamethasone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug: Carfilzomib + Dexamethasone (Drug: Carfilzomib + Dexamethasone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome inhibitor + corticosteroid combination. Area: Oncology.

marketed Proteasome inhibitor + corticosteroid combination 20S proteasome (carfilzomib); glucocorticoid receptor (dexamethasone) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Drug: Carfilzomib + Dexamethasone (Drug: Carfilzomib + Dexamethasone) — Amgen. Carfilzomib inhibits the proteasome to trigger cancer cell death, while dexamethasone is a corticosteroid that enhances anti-myeloma effects and reduces inflammation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Drug: Carfilzomib + Dexamethasone TARGET	Drug: Carfilzomib + Dexamethasone	Amgen	marketed	Proteasome inhibitor + corticosteroid combination	20S proteasome (carfilzomib); glucocorticoid receptor (dexamethasone)
Bortezomib +Dexamethasone regimen	Bortezomib +Dexamethasone regimen	Assistance Publique - Hôpitaux de Paris	phase 3	Proteasome inhibitor + corticosteroid combination	26S proteasome (bortezomib); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proteasome inhibitor + corticosteroid combination class)

Amgen · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Drug: Carfilzomib + Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-carfilzomib-dexamethasone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab